Endostatin抗肿瘤机制研究进展

Advances in the Research on the Anti-tumor Mechanism of Endostatin

肿瘤的生长转移与肿瘤血管生成密切相关,抗血管生成治疗是抑制肿瘤生长、防止肿瘤转移的新策略。Endostatin是1997年O`Reilly等从小鼠血管内皮瘤细胞(EOMA)的培养血清中分离出的一种新的内源性血管生成抑制剂。体内外实验证明,它可以特异性地作用于新生血管的内皮细胞,抑制内皮细胞的迁移、诱导其凋亡,从而抑制肿瘤新生血管形成和肿瘤生长。但近年来也有研究表明,Endostatin还可直接抑制某些肿瘤细胞的生长、诱导肿瘤细胞凋亡。Endostatin作为肿瘤抗血管生成治疗的新策略,已显示出良好的临床应用前景。但有关Endostatin的具体作用机制及信号传导通路尚不十分明确,现综述近年来有关Endostatin抗肿瘤机制研究的进展。

Tumor growth and metastasis are correlated with tumor angiogenesis. Antiangiogenesis therapy is a new strategy for inhibiting tumor growth and preventing tumor metastasis. Endostatin is an endogenous inhibitor of angiogenesis and was extracted for the first time from a murine hemangioendothelioma cell line （EOMA） by O＇Reilly in 1997. In vivo and in vitro experiments have shown that Endostatin can specifically target endothelial cells, inhibiting migration and inducing apoptosis, thereby inhibiting angiogenesis and tumor growth. Endostatin displays a favorable clinical perspective but its mechanism of action and signal transduction path are not yet thoroughly elucidated. Here we review the progress of research on the anti-tumor mechanism of Endostatin in recent years.